

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 01.03.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
(601) A1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	5 Weak positive (2+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	1 Negative (1+)	2,1 %
		>>>	8 Weak positive (2+)	17 %
		>	4 Strong positive (3+)	8,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	25 Weak positive (2+)	53 %
	(999) another manufacturer	>>>	4 Weak positive (2+)	8,5 %
Total per sample: n = 47		Success: 98 %		
Total success: 98 %				
(602) A2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>	1 Negative (0)	2,1 %
		>>>	4 Negative (1+)	8,5 %
	(803) Dako c-erbB-2 Onkoprotein	>	2 Negative (0)	4,3 %
		>>>	6 Negative (1+)	13 %
			5 Weak positive (2+)	11 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	7 Negative (0)	15 %
		>>>	16 Negative (1+)	34 %
			2 Weak positive (2+)	4,3 %
	(999) another manufacturer	>	2 Negative (0)	4,3 %
		>>>	2 Negative (1+)	4,3 %
Total per sample: n = 47		Success: 85 %		
Total success: 85 %				
(603) A3 expression HER-2/neu				
Slide	(802) Dako HercepTest	±	2 Negative (1+)	5,7 %
	(803) Dako c-erbB-2 Onkoprotein	±	3 Negative (0)	8,6 %
		±	3 Negative (1+)	8,6 %
		±	5 Weak positive (2+)	14 %
	(804) Ventana PATHWAY anti-HER-2/neu	±	2 Negative (0)	5,7 %
		±	14 Negative (1+)	40 %
		±	3 Weak positive (2+)	8,6 %
	(999) another manufacturer	±	2 Negative (1+)	5,7 %
		±	1 Weak positive (2+)	2,9 %
Total per sample: n = 35		Success (only evaluated results): evaluation		
(606) B1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	5 Strong positive (3+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>	3 Weak positive (2+)	6,4 %
		>>>	10 Strong positive (3+)	21 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	25 Strong positive (3+)	53 %
	(999) another manufacturer	>>>	4 Strong positive (3+)	8,5 %
Total per sample: n = 47		Success: 100 %		
Total success: 100 %				
(607) B2 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	2 Negative (0)	4,3 %
		>	2 Negative (1+)	4,3 %
			1 Weak positive (2+)	2,1 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	23 %
		>	2 Negative (1+)	4,3 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	25 Negative (0)	53 %
	(999) another manufacturer	>>>	4 Negative (0)	8,5 %
Total per sample: n = 47		Success: 98 %		
Total success: 98 %				
(608) B3 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	3 Negative (0)	7,1 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	12 Negative (0)	29 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	23 Negative (0)	55 %
	(999) another manufacturer	>>>	4 Negative (0)	9,5 %
Total per sample: n = 42		Success: 100 %		
Total success: 100 %				
(611) C1 expression HER-2/neu				
Slide	(802) Dako HercepTest	>>>	5 Strong positive (3+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	13 Strong positive (3+)	28 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	25 Strong positive (3+)	53 %
	(999) another manufacturer	>>>	4 Strong positive (3+)	8,5 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 01.03.2022

Test			N	Result	N _{rel}
Sample	Group				
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(612) C2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	5	Strong positive (3+)	11 %
	(803) Dako c-erbB-2 Onkoprotein	>	2	Weak positive (2+)	4,3 %
		>>>	11	Strong positive (3+)	23 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	25	Strong positive (3+)	53 %
	(999) another manufacturer	>>>	4	Strong positive (3+)	8,5 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(613) C3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	6	Strong positive (3+)	13 %
	(803) Dako c-erbB-2 Onkoprotein	>	2	Weak positive (2+)	4,3 %
		>>>	10	Strong positive (3+)	21 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	25	Strong positive (3+)	53 %
	(999) another manufacturer	>>>	4	Strong positive (3+)	8,5 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(616) D1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	4	Weak positive (2+)	8,5 %
		>	1	Strong positive (3+)	2,1 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1+)	2,1 %
		>>>	7	Weak positive (2+)	15 %
		>	5	Strong positive (3+)	11 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Weak positive (2+)	51 %
		>	1	Strong positive (3+)	2,1 %
	(999) another manufacturer	>>>	4	Weak positive (2+)	8,5 %
Total per sample: n = 47		Success: 98 %			
Total success: 98 %					
(617) D2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	3	Weak positive (2+)	6,4 %
		>	2	Strong positive (3+)	4,3 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1+)	2,1 %
		>>>	7	Weak positive (2+)	15 %
		>	5	Strong positive (3+)	11 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Weak positive (2+)	51 %
		>	1	Strong positive (3+)	2,1 %
	(999) another manufacturer	>>>	3	Weak positive (2+)	6,4 %
		>	1	Strong positive (3+)	2,1 %
Total per sample: n = 47		Success: 98 %			
Total success: 98 %					
(618) D3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	5	Weak positive (2+)	11 %
	(803) Dako c-erbB-2 Onkoprotein		1	Negative (1+)	2,1 %
		>>>	8	Weak positive (2+)	17 %
		>	4	Strong positive (3+)	8,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Weak positive (2+)	51 %
		>	1	Strong positive (3+)	2,1 %
	(999) another manufacturer	>>>	4	Weak positive (2+)	8,5 %
Total per sample: n = 47		Success: 98 %			
Total success: 98 %					
(621) E1 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	3	Negative (1+)	6,4 %
			2	Weak positive (2+)	4,3 %
	(803) Dako c-erbB-2 Onkoprotein	>	1	Negative (0)	2,1 %
		>>>	8	Negative (1+)	17 %
			4	Weak positive (2+)	8,5 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	4	Negative (0)	8,5 %
		>>>	19	Negative (1+)	40 %
			2	Weak positive (2+)	4,3 %
	(999) another manufacturer	>	1	Negative (0)	2,1 %
		>>>	2	Negative (1+)	4,3 %
			1	Weak positive (2+)	2,1 %
Total per sample: n = 47		Success: 81 %			
Total success: 81 %					
(622) E2 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	1	Negative (0)	2,1 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 01.03.2022

Test			N	Result	N _{rel}
Sample	Group				
Slide	(802) Dako HercepTest	>>>	3	Negative (1+)	6,4 %
			1	Weak positive (2+)	2,1 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	3	Negative (0)	6,4 %
		>>>	8	Negative (1+)	17 %
			2	Weak positive (2+)	4,3 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	9	Negative (0)	19 %
		>>>	15	Negative (1+)	32 %
			1	Weak positive (2+)	2,1 %
	(999) another manufacturer	>>>	1	Negative (0)	2,1 %
		>>>	2	Negative (1+)	4,3 %
			1	Weak positive (2+)	2,1 %
Total per sample: n = 47		Success: 89 %			
Total success: 89 %					
(623) E3 expression HER-2/neu					
Slide	(802) Dako HercepTest	>>>	4	Negative (1+)	8,5 %
			1	Weak positive (2+)	2,1 %
	(803) Dako c-erbB-2 Onkoprotein	>	3	Negative (0)	6,4 %
		>>>	8	Negative (1+)	17 %
			2	Weak positive (2+)	4,3 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	4	Negative (0)	8,5 %
		>>>	17	Negative (1+)	36 %
			4	Weak positive (2+)	8,5 %
	(999) another manufacturer	>	1	Negative (0)	2,1 %
		>>>	2	Negative (1+)	4,3 %
			1	Weak positive (2+)	2,1 %
Total per sample: n = 47		Success: 83 %			
Total success: 83 %					
(651) A1 sample staining					
Slide	(0) not specified		1	0 points	2,1 %
		>	10	3 points	21 %
		>>>	36	6 points	77 %
Total per sample: n = 47		Success: 98 %			
Total success: 98 %					
(652) A2 sample staining					
Slide	(0) not specified	>	1	3 points	2,1 %
		>>>	46	6 points	98 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(656) B1 sample staining					
Slide	(0) not specified	>	8	3 points	17 %
		>>>	39	6 points	83 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(657) B2 sample staining					
Slide	(0) not specified	>>>	47	6 points	100 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(658) B3 sample staining					
Slide	(0) not specified	>>>	42	6 points	100 %
Total per sample: n = 42		Success: 100 %			
Total success: 100 %					
(661) C1 sample staining					
Slide	(0) not specified	>	1	4 points	2,1 %
		>>>	46	6 points	98 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(662) C2 sample staining					
Slide	(0) not specified	>	6	3 points	13 %
		>>>	41	6 points	87 %
Total per sample: n = 47		Success: 100 %			
Total success: 100 %					
(663) C3 sample staining					
Slide	(0) not specified		1	0 points	2,1 %
		>	3	3 points	6,4 %
		>>>	43	6 points	91 %

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: IHC1/22 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 01.03.2022

Test		N	Result	N _{rel}
Total per sample: n = 47		Success: 98 %		
Total success: 98 %				
(666) D1 sample staining				
Slide	(0) not specified	> 9	3 points	19 %
		>>> 38	6 points	81 %
Total per sample: n = 47		Success: 100 %		
Total success: 100 %				
(667) D2 sample staining				
Slide	(0) not specified	1	1 point	2,1 %
		> 12	3 points	26 %
		>>> 34	6 points	72 %
Total per sample: n = 47		Success: 98 %		
Total success: 98 %				
(668) D3 sample staining				
Slide	(0) not specified	2	0 points	4,3 %
		> 11	3 points	23 %
		>>> 34	6 points	72 %
Total per sample: n = 47		Success: 96 %		
Total success: 96 %				
(671) E1 sample staining				
Slide	(0) not specified	> 4	3 points	8,5 %
		>>> 43	6 points	91 %
Total per sample: n = 47		Success: 100 %		
Total success: 100 %				
(672) E2 sample staining				
Slide	(0) not specified	> 2	3 points	4,3 %
		>>> 45	6 points	96 %
Total per sample: n = 47		Success: 100 %		
Total success: 100 %				
(673) E3 sample staining				
Slide	(0) not specified	> 3	3 points	6,4 %
		>>> 44	6 points	94 %
Total per sample: n = 47		Success: 100 %		
Total success: 100 %				
(681) IQC				
Slide	(0) not specified	16	0 points	34 %
		> 10	3 points	21 %
		>>> 1	5 points	2,1 %
		>>> 20	6 points	43 %
Total per sample: n = 47		Success: 66 %		
Total success: 66 %				